Product Reports Resources Pricing Login Book a demo

Glaukos

Biotech & Life Sciences · Aliso Viejo, United States · Founded 1998 · IPO 2015

Breakthrough products and procedures to transform the treatment of glaucoma, one of the world’s leading causes of blindness

Valuation $9.65B
Revenue $691M
EBITDA $5.8M
Power Law Unicorn$1–10B valuation tier Thoroughbred$100M+ revenue

Investors

15 investors on Glaukos's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series A 6 investors entered at this stage
Versant Ventures
DeNovo Ventures
Borealis Ventures
Domain Associates
Prism Venture Management
Frazier Healthcare Partners
Series B+ 9 investors entered at this stage
Meritech Capital
University of California
Irvine
Fjord Ventures
InterWest Partners
OrbiMed
Caltech
California Institute of Technology
Montreux Equity Partners

Glaukos mafia

Startups founded by Glaukos alumni

Former Glaukos employees who went on to start their own companies. Sorted by Dealroom signal score.

Stylus MedicineEst. 2022
Joshua ResnickUnited States
Signal score80
VentriJectEst. 2018
Stig Visti AndersenDenmark
Signal score79
Remedium bioEst. 2020
Alex GoraltchoukUnited States
Signal score77
CloraEst. 2016
Rahul ChaturvediUnited States
Signal score76
Nalu MedicalEst. 2014
Mike PartschUnited States
Signal score76
InveniasEst. 2005
Richard HarrisonUnited Kingdom
Signal score65
KSQ TherapeuticsEst. 2015
David BerryUnited States
Signal score63

Book a demo to explore the full alumni network →

Global footprint

Where Glaukos has talent and traffic

Workforce by country
23 countries with
team presence
🇺🇸 United States83.7%
🇩🇪 Germany2.8%
🇬🇧 United Kingdom2%
🇧🇷 Brazil1.7%
🇦🇺 Australia1.4%
Top 5 of 23 shown
Web traffic by country
31K monthly visits
across markets
🇺🇸 United States46.1%
🇬🇧 United Kingdom11.9%
🇦🇺 Australia6.8%
🇮🇳 India6.8%
🇲🇽 Mexico6.1%
Top 5 markets shown

Talent graph

The shape of Glaukos's talent

Dealroom maps Glaukos's team person by person — pinpointing the standout operators and scoring them across the six dimensions investors underwrite. The counts and shape below are a public preview; the named individuals and exact scores live in the platform.

23 standout operatorsDealroom-flagged across the org
1 AI specialistpinpointed by name
1,125 employees mappedperson by person
DimensionScore
AI Talentlive Score hidden — book a demo
Engineering Score hidden — book a demo
Product Score hidden — book a demo
Go-to-market Score hidden — book a demo
Leadership Score hidden — book a demo
Research Score hidden — book a demo
Book a demo to unlock Glaukos's exact scores

Source: Dealroom Talent Intelligence. Public profiles show counts and the team's shape only — request a demo for the named individuals, per-person seniority and tenure, and team benchmarks vs peers.

Patent intelligence

$156M patent portfolio · 133 active families

Estimated portfolio value
$156M
1.6% of market cap · 2.3× smaller than top peer NovoCure ($352M)
133 active patent families
Where Glaukos innovates Biomedical engineeringCorneaOphthalmologyOptometryAqueous humor

Where Glaukos concentrates vs peers

Each axis is a top-10 topic across Glaukos and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Market sentiment

What the market is saying about Glaukos

An AI-synthesized read of the highest-engagement posts about Glaukos on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Glaukos on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles